Novozymes traded at 381.20 this Tuesday April 21st, decreasing 0.60 or 0.16 percent since the previous trading session. Looking back, over the last four weeks, Novozymes lost 8.70 percent. Over the last 12 months, its price fell by 1.58 percent. Looking ahead, we forecast Novozymes to be priced at 362.50 by the end of this quarter and at 311.98 in one year, according to Trading Economics global macro models projections and analysts expectations.
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Bayer and Syngenta in Agriculture and DSM and Adisseo in Animal Health & Nutrition..